StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Lorbrena / Lorviqua (lorlatinib by Year

Lorbrena / Lorviqua (lorlatinib — ALK+ NSCLC) — Worldwide operational (constant-currency) YoY (%) (%)

Pfizer Lorbrena / Lorviqua (lorlatinib: 40.0% in FY2025, up 3.0 pts from a year earlier.

Latest, FY2025
40.0%
Period ended Dec 31, 2025
Change on a year earlier
+3.0 pts
37.0% in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below

Where the FY2025 figure comes from

“|| Lorbrena | 1,023 | 731 | 40% | 40% | 407 | 306 | 33% | 616 | 424 | 45% | 44%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Pfizer Lorbrena / Lorviqua (lorlatinib (%), annual FY2020–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/lorbrena-oper-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.